CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 564 enrolled
Drug / intervention
liraglutide +2 moredrug
Likely dose
orlistat 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00422058
NCT00422058Phase 2Completed
CompareCT.gov

Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes: A 20-week Randomised, Double-blind, Placebo-controlled, Six Armed Parallel Group, Multi-centre, Multinational Trial With an Open Label Orlistat Comparator Arm and With an 84-week Extension Period

Novo Nordisk A/S·interventional·Posted Jan 15, 2007·Updated Nov 1, 2017

In Brief

A Phase 2 clinical trial evaluating liraglutide, orlistat, and 1 other intervention for Metabolism and Nutrition Disorder and Obesity. Completed, enrolled 564 participants across 19 sites in 8 countries.

Detailed Summary

This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long term safety and tolerability of liraglutide. Trial has the following trial periods: A 20-week randomised, double-blind, placebo-controlled, six-armed parallel-group, multi-centre, multinational trial with an open label orlistat comparator arm followed by an 84 week extension period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolism and Nutrition Disorder, Obesity
CountriesBelgium, Czechia, Denmark, Finland, Netherlands, Spain, Sweden, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 15, 2007
Enrollment StartJan 10, 2007
Primary CompletionSep 13, 2007
Study CompletionApr 30, 2009
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 19.5 years ago

Interventions

liraglutidedrug

Injected s.c. (under the skin) once daily

orlistatdrug

120 mg capsule. Administered thrice daily

placebodrug

Injected s.c. (under the skin) once daily